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Abstract
Background: Membranoproliferative glomerulonephritis (MPGN) with immune complexes and C3 glomerulopathy (C3G) in
children are rare and have a variable outcome, with some patients progressing to end-stage renal disease (ESRD). Mutations
in genes encoding regulatory proteins of the alternative complement pathway and of complement C3 (C3) have been
identified as concausative factors.
Methods: Three children with MPGN type I, four with C3G, i.e. three with C3 glomerulonephritis (C3GN) and one with dense
deposit disease (DDD), were followed. Clinical, autoimmune data, histological characteristics, estimated glomerular
filtration rate (eGFR), proteinuria, serum C3, genetic and biochemical analysis were assessed.
Results: The median age at onset was 7.3 years and the median eGFR was 72 mL/min/1.73 m2. Six children had marked
proteinuria. All were treated with renin–angiotensin–aldosterone system (RAAS) blockers. Three were given one or more
immunosuppressive drugs and two eculizumab. At the last median follow-up of 9 years after diagnosis, three children had
normal eGFR and no or mild proteinuria on RAAS blockers only. Among four patients without remission of proteinuria,
genetic analysis revealed mutations in complement regulator proteins of the alternative pathway. None of the three
patients with immunosuppressive treatment achieved partial or complete remission of proteinuria and two progressed to
ESRD and renal transplantation. Two patients treated with eculizumab revealed relevant decreases in proteinuria.
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Conclusions: In children with MPGN type I and C3G, the outcomes of renal function and response to treatment modality
show great variability independent from histological diagnosis at disease onset. In case of severe clinical presentation at
disease onset, early genetic and biochemical analysis of the alternative pathway dysregulation is recommended. Treatment
with eculizumab appears to be an option to slow disease progression in single cases.
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Introduction
Membranoproliferative glomerulonephritis (MPGN) with
immune complexes is a rare chronic glomerulonephritis in
childhood characterized by proteinuria (up to the nephrotic
range), haematuria, hypertension and often impaired renal
function at disease onset [1]. In up to 50% of affected children,
MPGN leads to renal failure within 10 years [2]. Impaired renal
function after 1 year of onset is considered a risk factor for poor
renal outcome and end-stage renal disease (ESRD) [1]. The
recurrence rate after renal transplantation (RTPL) is high (up to
45%) [1–4]. MPGN may occur as a primary genetic disorder or
secondary to chronic diseases, including infections (e.g. hepati-
tis B or C), systemic lupus erythematosus, liver disease and
malignancies.
In the past, MPGN was diagnosed and classified by renal his-
tological features and grouped into three pathological subtypes
with different aetiologies and pathogenesis, types I, II [(dense
deposit disease (DDD)] and III [5]. Activation of the alternative
complement pathway has repeatedly been observed in conjunc-
tion with low serum levels of complement C3 (C3) [6–8]. A link
between dysregulation of the alternative complement pathway
and the pathogenesis of MPGN was assumed [7] and has
recently been confirmed by findings of mutations in the genes
of complement factor H (CFH) and CF-related proteins (CFHR) in
DDD [9–13].
Therefore the histological classification has been reconsid-
ered recently on the basis of pathogenesis and with division
into those cases in which the glomerular immune deposits stain
for immunoglobulins and complement and those cases that are
characterized by C3 deposition alone [5, 14–16]. The term ‘C3
glomerulopathy’ (C3G) encompassed complement-mediated
renal disease, and therefore incorporates disease entities where
the presence of a disease-associated complement mutation is
causally associated with the underlying renal pathology.
Examples include DDD and C3 glomerulonephritis (C3GN) [5].
The term C3GN was coined to describe glomerular lesions in
which there is glomerular accumulation of C3 with little or no
immunoglobulin in the absence of the characteristic highly
electron-dense transformation seen in DDD [16]. The incidence
of C3G is estimated to be 1–2 per 106 children [17, 18], with dis-
ease recurrence after RTPL reported at between 30 and 77% and
a graft failure due to recurrence in 17–50% of the recipients
[19, 20]. MPGN associated with the presence of immunoglobu-
lins and complement has been termed immune complex–medi-
ated MPGN by Sethi and Fervenza [21]. Immune complex-
mediated MPGN is commonly associated with autoimmune dis-
ease and chronic infection and can be associated with mixed
cryoglobulinaemia or monoclonal gammopathy [5, 21]. These
associations were excluded in our study. In our series, histologi-
cal MPGN I is a case of so-called idiopathic MPGN. MPGN I and
C3G are regarded as heterogeneous diseases, with several stud-
ies reporting complement mutations in complement genes [15,
22]. So far there are no evidence-based guidelines for treatment
of MPGN I [1, 2] and C3G. The mainstay of treatment in MPGN I
and C3G is based on single-centre studies and expert opinions.
Clinical trials in adults and children with different treatment
modality propositions [e.g. immunosuppressant agents, anti-
platelet drugs and plasmapheresis (PEX)] are described [23–29].
Treatment with renin–angiotensin–aldosterone system (RAAS)
blockers are described to induce a decrease in proteinuria and
delays progression to ESRD in many glomerular diseases in
adults [30, 31] and in some glomerulopathies in children [32, 33];
however, there is no evidence for beneficial effect in children
with MPGN I [34] and spontaneous recovery in C3GN can also
not be excluded [22].
Eculizumab is a monoclonal antibody binding to C5 and
thereby inhibiting the complement system and preventing acti-
vation of the alternative pathway. Recently, promising results
were shown in selected patients with MPGN and C3GN charac-
terized by the presence of alterations in regulatory proteins of
the alternative complement pathway [22, 35–37].
We evaluated the outcome of seven children with the diag-
nosis of MPGN I, C3GN and DDD. All were screened for the pres-
ence of genetic mutations of the alternative complement
pathway. We analysed the benefit of different administered
treatments.
Materials and methods
All patients with histologically diagnosed MPGN I, DDD and
C3GN who were seen at the University Children’s Hospital
Zurich between 2003 and 2015 were included in a retrospective
data analysis. Clinical assessment included diagnosis, sex, med-
ical history, clinical examination, blood pressure (BP) and analy-
sis to exclude potentially secondary forms of MPGN.
Biochemical and genetic analysis
Plasma creatinine, total serum protein and albumin and urinary
protein:creatinine ratio (UPCR) were analysed at disease onset
and at the last follow-up. Blood samples for complement regu-
lator protein analysis were centrifuged immediately after col-
lection and frozen at80C prior to analysis. C3 serum levels
were evaluated by kinetic nephelometry (Immage 800, Beckman
Coulter, Brea, CA, USA) with a normal value>0.7 g/L (reference
value of the immunology laboratory of Zurich University
Children’s Hospital). The soluble complement components C5b-
9 (membrane attack complex), C3d and C3 nephritic factor
(C3NeF) were measured from plasma samples at the Institute
for Immunology of Heidelberg University (Heidelberg,
Germany). The following biochemical analyses were performed
at follow-up from plasma and serum, as well as ethylenediami-
netetraacetic acid blood samples for genetic analysis (samples
at the Leibniz Institute for Natural Product Research and
Infection Biology, Jena, Germany): CFH antibody, C3-convertase
antibody, CFI, CFB, CFHR1, CFHR2, CFHR3, CFHR4, CFHR5, MCP
(CD46) and by next-generation sequencing (NGS) at the Center
for Human Genetics at Bioscientia in Ingelheim (Germany), as
described in detail below.
480 | G. Sparta` et al.
Downloaded from https://academic.oup.com/ckj/article-abstract/11/4/479/4915394
by ejournal@library.ethz.ch user
on 21 August 2018
Targeted NGS using a customized multigene panel for atypi-
cal hemolytic uremic syndrome (aHUS) and related disorders
was performed in all patients [38]. In brief, we utilized a custom-
ized sequence capture library that targets exons and addition-
ally 35 bp of flanking intronic sequence (20–23). Genomic DNA
was fragmented and the coding exons of the analysed genes, as
well as the corresponding exon–intron boundaries, were
enriched using the Roche/NimbleGen sequence capture
approach (NimbleGen, Madison, WI, USA), amplified and
sequenced simultaneously by Illumina NGS sequencing-by-
synthesis technology using a HiSeq 1500 system (Illumina, San
Diego, CA, USA). Target regions were usually sequenced with an
average coverage of  400–500-fold. With this method, 20-fold
coverage is obtained for >99.5% of the regions of interest. NGS
data analysis was performed using bioinformatic analysis tools
and JSI Medical Systems software (version 4.1.2; JSI Medical
Systems, Kippenheim, Germany). Identified variants and indels
were filtered against external and internal databases and
depending on allelic frequency. The focus was on rare variants
with a minor allele frequency of 1%. Nonsense, frameshift
and canonical splice site variants were considered a priori as
likely to be pathogenic. Pathogenicity of identified non-
synonymous variants was assessed using bioinformatic predic-
tion programs, such as Mutation Taster, Polyphen-2,
MutationAssessor and FATHMM. Only those variants predicted
by the majority of algorithms used to be probably damaging
were considered likely to be pathogenic. In silico analysis of
splice site effects was performed using bioinformatic programs
such as Fruitfly, NetGene2, Human Splicing Finder, Mutation
Taster and ESEFinder. Mapping and coverage statistics were
generated from the mapping output files using GATK. The
resulting sequence data were compared with the reference
sequence of the RefSeq database. High coverage enabled copy
number variation analysis. Potential copy number alterations
were initially identified by VarScan on mapped reads. In this
way, coverage of every target region of the sample was inter-
nally normalized and compared with normalized control data
of other samples of the same run by VarScan copy number
mode and standard settings. Putative pathogenic differences
between the wild-type sequence (human reference genome
according to the University of California, Santa Cruz Genome
Browser: hg19, GRCh37) and the patient’s sequence were vali-
dated by conventional Sanger sequencing and, in the case of
copy number variation, by multiplex ligation-dependent probe
amplification.
Renal biopsy
All patients underwent native kidney biopsy at disease onset.
Repeated renal biopsy was performed in two children, one of
the native kidneys and one in the transplanted kidney. The
biopsy diagnosis was based on the current classification and
nomenclature for C3G and MPGN [5, 16] on findings by light
microscopy (LM), immunofluorescence (IF) and electron micro-
scopy (EM).
Definitions
The following definitions were used: nephrotic-range proteinuria:
UPCR >250 g/mol; nephrotic syndrome: serum albumin<25 g/L,
nephrotic-range proteinuria and generalized oedema; remission:
UPCR <20 g/mol; partial remission: UPCR >20–<80 g/mol; normal
renal function: estimated glomerular filtration rate
(eGFR)>90 mL/min/1.73 m2, as calculated by the Schwartz
formula using a local k-factor of 40 [39]; hypertension: casual sys-
tolic BP>95th percentile for sex and height [40].
Treatment
All patients were given RAAS blockers as first-line antiproteinu-
ric therapy. Additional treatment consisted of prednisolone
(PDN), in accordance with the dosage regimen for treatment of
children with steroid-resistant nephrotic syndrome [41, 42].
Further immunosuppressive treatment [cyclosporine A (CSA)
and mycofenolate mofetile (MMF)] [25, 42] was administered to
patients who failed to attain partial or full remission of protei-
nuria. Eculizumab has been available in our hospital since 2013,
but costs were not covered by all insurances, as this drug is still
off-label for MPGN/C3G treatment. Eculizumab was given to two
patients with nephrotic-range proteinuria despite immunosup-
pressive and RAAS blocker treatment. The dosage followed cur-
rent recommendations for aHUS [43]. Patients treated with
eculizumab were immunized with meningococcal vaccine
(Menveo, GlaxoSmithKline Biologicals, Rixensart, Belgium)
4 weeks prior to administration. Informed consent was obtained
from all parents of included patients for medical data collection,
genetic analysis and treatment with eculizumab.
Results
Seven children (four boys and three girls) fulfilled the inclusion
criteria (Table 1): three patients suffered from MPGN I, three from
C3GN and one from DDD. The median age at onset was 7.3 years
(range 2.5–12.5) with a median eGFR of 72 mL/min/1.73 m2 (range
41–140) at diagnosis.
Table 1. Patient characteristics at disease onset
Characteristics Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Age (years) 7.3 2.5 6 12.5 5.9 10.5 8.8
Sex Male Male Female Female Male Female Male
Hypertension No No No No No Yes Yes
Haematuria Micro Micro Macro Micro Macro Micro Micro
UPCR (g/mol) (reference <20) 634 126 530 855 580 1500 1000
Nephrotic syndrome (UPCR >250 g/mol) No No No Yes No Yes Yes
Serum albumin (g/L) (reference 35–51) 27 32 26 11 30 12 12
eGFR (mL/min/1.73 m2) (reference >90) 72 140 41 67 88 65 95
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Analysis of the alternative complement pathway: CFs
and genetic testing
All children showed persistently low serum C3 (Table 2). In
addition, C3NeF was negative in all but one patient and C3b
antibodies were positive in two children with C3GN.
At the last follow-up (Tables 3–5), C3d was elevated in five
patients and sC5b-9 levels were increased in four children, both
in MPGN I and C3GN.
Renal biopsy
Renal biopsy findings (MPGN I, C3GN and DDD) (Figures 1–4) are
presented in Table 2. Repeated renal biopsy was performed in
Patient 4 (native kidney, before embarking on MMF) and Patient
7 (renal graft for suspected acute graft rejection). The diagnoses
were made based on IF findings. As the IF slides were no longer
available, the figures contain pictures of immunohistochemis-
try performed for the purpose of the publication.
Treatment regimens and follow-up
The median follow-up was 9 years (range 2.2–11.5). Five children
maintained renal function of their native kidneys, with a
median eGFR of 107 mL/min/1.73 m2 (range 40–180), including
four patients with normal eGFR. Two children reached ESRD
and underwent RTPL with initially good renal graft function. All
children had BP < 95th percentile, with six on RAAS blockers: in
one child, RAAS blockers were stopped after RTPL. All children
exhibited persistent haematuria. Three patients with nephrotic
syndrome (Patients 4, 6 and 7) exhibited progression of
proteinuria on PDN and were given additional immunosuppres-
sive treatment.
Patients with RAAS blockers only
Patients 1–3 (MPGN I, n52; C3GN, n51) (Table 3). All had nor-
mal renal function at onset without signs of a nephrotic syn-
drome. Follow-up was uneventful, with partial or complete
remission of proteinuria and maintained normal renal function.
All had persistently low C3. Genetic testing revealed a risk hap-
lotype for the membrane cofactor protein (MCP/CD46) gene in
all three children. In addition, Patient 2 (MPGN I) had elevated
sC5b-9 and a heterozygous mutation in the CFHR5 gene.
Patients with additional immunosuppressive
treatments, including eculizumab
Patient 4 (MPGN I) (Tables 4). Because of progressive proteinuria
on PDN, MMF was started [25]. Daily proteinuria initially
decreased from 4 to 2 g. However, impaired renal function and
nephrotic-range proteinuria persisted with elevated alternative
pathway activity. A second renal biopsy confirmed the diagno-
sis of MPGN I. Therefore MMF was discontinued and eculizumab
was started. Six months after starting eculizumab, a significant
decrease in proteinuria and sC5b-9 was observed with stabiliza-
tion of eGRF.
Patient 5 (C3GN) (Tables 4). Because of increasing proteinuria
with normal renal function and persistently elevated alterna-
tive pathway activity despite RAAS blockade, the treatment
Fig. 1. DDD native kidney (Patient 7). (A) Glomeruli with mesangial and endocapillary proliferation and a fibrocellular crescent [hematoxylin and eosin (H&E) stain, orig-
inal magnification 200]. (B) Intramembranous and mesangial deposits (acid fuchsin orange G stain, original magnification 200). (C and D) EM with highly osmiophilic
electron-dense deposits in the lamina densa of the glomerular basement membrane and mesangium (original magnification 1100 and 1950).
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with eculizumab was initiated [43]. After 11 months, proteinuria
and sC5b-9 level decreased, whereas C3NeF remained positive.
Renal function remained stable at a normal level.
Patient 6 (C3GN) (Table 5). Nephrotic-range proteinuria per-
sisted despite additional treatment with CSA for 6 years. The
child reached ESRD and underwent peritoneal dialysis 6.5 years
after disease onset. Deceased-donor RTPL was performed;
immunosuppression included tacrolimus, MMF, PDN and induc-
tion therapy with basiliximab. RAAS blocker was stopped.
Seven months after transplantation, sC5b-9 was still slightly
elevated. Renal graft function remained stable without
proteinuria.
Patient 7 (DDD) (Table 5). Additional treatment with CSA was
started due to persistent nephrotic-range proteinuria. The child
reached ESRD 4.2 years after disease onset. Living paternal-donor
RTPL was performed; immunosuppression included CSA, MMF
and PDN. The child experienced acute/active antibody-mediated
rejection (aABMR) and recurrence of DDD in the graft 3.3 years
Fig. 2. DDD recurrence in transplant biopsy (Patient 7). (A) Thickened, glassy GBM and endocapillary hypercellularity with mononuclear cells (H&E stain, original mag-
nification 200). (B) Intramembranous deposits and endocapillary proliferation (AFOG stain, original magnification 324). (C) Immunohistochemistry positive for C3
(original magnification 200). (D) Immunohistochemistry negative for immunoglobulin G (original magnification 200). (E and F) EM with highly osmiophilic electron-
dense deposits in the lamina densa and subepithelial humps (original magnification 1000 and 2500).
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after transplantation Therefore treatment with CSA was switched
to tacrolimus and PEX was started [1.5-fold plasma volume
exchange with fresh frozen plasma (FFP)], but ESRD occurred
3.9 years after RTPL. A deceased-donor RTPL was then performed.
Immunosuppression included tacrolimus, MMF, PDN and induc-
tion with thymeoglobulin. Again, ABMR and recurrence of the dis-
ease with nephrotic proteinuria occurred 15 months after
retransplantation. Weekly treatment with PEX reduced proteinu-
ria, but proteinuria increased when the PEX interval was extended
to every second week. Measurement of sC5b-9 (after PEX session)
showed normal values. Renal graft function was impaired (eGFR
42 mL/min/1.73 m2) at the last follow-up.
Discussion
MPGN and C3G are rare diseases with chronic progressive glo-
merulonephritis and children may have an unfavourable course
leading to ESRD [17, 18, 44, 45]. Studies in adults and children
have shown that proteinuria is a major risk factor for develop-
ing ESRD [1, 46, 47]. In the last decade, new insights are
Fig. 3. MPGN I (Patient 1). (A) Mesangial and endocapillary proliferation (periodic acid–Schiff stain, original magnification 110). (B) Splitting of the GBM (silver methen-
amine stain, original magnification 220). (C) Subendothelial deposits (AFOG stain, original magnification 200). (D) Immunhistochemistry positive for IgG (original
magnification 280), inset: positivity for C3 (original magnification 220). (E) EM with mostly subendothelial and some subepithelial and mesangial electron-dense
deposits (original magnification 1950). (F) Subendothelial and small subepithelial electron-dense deposits (original magnification 10 500).
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emerging to improve genetic and biochemical investigations of
these diseases.
Currently there is no established treatment for MPGN and C3G.
Patients appear to respond differently to various therapy modal-
ities [27, 29, 48, 49]. The majority of treatment regimens and case
series have been reported in adults, not in children [23, 26], and are
often associated with significant side effects. Recently, treatment
with eculizumab, a monoclonal antibody binding to C5 of the
alternative pathway, has shown promising results in the treatment
of some cases of MPGN and C3G [22, 35–37, 50].
Our analysis revealed a dysregulation of the complement
alternative pathway and mutation/variation in genes of CF pro-
teins in children with MPGN, C3GN and DDD. Three patients of
our series showed a favourable outcome. These were two
patients with MPGN I and one with C3GN, the latter without any
genetic variation in CFHR proteins. Five of seven children had a
Fig. 4. C3GN (Patient 6). (A) Mesangial and endocapillary proliferation (H&E stain, original magnification 100). (B) Mesangial and GBM deposits (AFOG stain, original
magnification 200). (C) Immunohistochemistry positive for C3 (original magnification 200). (D) Immunohistochemistry negative for IgG (original magnification
200). (E) EM with mostly intramembranous and mesangial not very dense electron-dense deposits (original magnification 300). (F) EM with subepithelial, intramem-
branous and subendothelial deposits (original magnification 2000).
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heterozygous mutation/deletion or variation in CFHR proteins 1,
2, 3 or 5. Recent findings show that dysregulation of the comple-
ment pathway by CFHR2–CFHR5 hybrid protein leads to
enhanced C3-convertase activation of the alternative comple-
ment pathway and other genetic complement abnormalities
associated with MPGN [12, 17, 51]. In our patients, genetic alter-
ations, including variation or polymorphisms, may at least in
part explain the different outcomes and responses to the vari-
ous treatment modalities. Similar findings are described by
other authors, where the clinical presentation and the measure-
ment of plasma C3, C3d and sC5b-9 do not allow differentiation
between C3G and MPGN I [22]. Recent knowledge suggests that
in idiopathic MPGN—an immune complex Rixensart, Belgium
mediated disease—involvement of the alternative pathway
plays an important role [17, 52].
Three of seven of our patients (two with MPGN and one with
C3GN) without nephrotic syndrome showed remission of protei-
nuria on RAAS blocker therapy only. No significant reduction in
proteinuria is described in children with MPGN treated with
RAAS blocker only. Other data revealed that patients with less
parenchymal damage in their initial renal biopsy benefit the
most from sole treatment with RAAS blocker [1]; however,
spontaneous remission may not be excluded [22]. Consistent
with other authors [1], those children of our series with neph-
rotic syndrome at onset showed a more severe course, with two
progressing to ESRD followed by RTPL.
Eculizumab has been described as a successful treatment of
patients with MPGN [35, 50, 53–55] and C3G [19, 22, 56] in several
reports. Elevated sCb5-9 levels may be a predictor of response to
treatment with eculizumab, but other factors affecting response
to therapy are poorly understood [53, 55]. Two patients of our
series, one with C3GN and one with MPGN I, exhibited a signifi-
cant decrease in proteinuria on eculizumab in their native kid-
neys, but elevated activity of the alternative pathway persisted.
This is consistent with observations of other paediatric patients
with MPGN [50] suggesting that eculizumab is not completely
effective in suppressing sC5b-9 activity in C3G. They hypothe-
sized that sC5b-9 alone may not reflect disease activity. The
presence of mutations alone does not significantly increase the
risk of developing idiopathic MPGN or C3G, but they do so when
combined with common susceptibility variants [i.e. in CD46,
CFH or Thrombomodulin (THBD)] [17, 52].
C3NeF, an auto-antibody directed against the alternative C3-
convertase, was positive at follow-up in only one child of our
series. Published reports on the impact of C3NeF on outcome in
C3G patients are inconsistent, with reported patients ranging
from complete remission to ESRD [57, 58]. Apparently C3NeF
can fluctuate during the clinical course independent of the dis-
ease treatment [22]. Others observed a higher risk of progressing
to ESRD in patients without complement gene mutation or
C3NeF, stabilizing the alternative pathway C3-convertase [52].
In our patient, C3NeF and a heterozygous variation of CFHR1
and CFHR1/3 was found. In addition, sC5b-9 was significantly
elevated. Other treatments, for example, rituximab and PEX, are
controversially discussed in the literature with different results
[52, 58, 59]. Therefore, after a risk–benefit evaluation of these
treatment options, we decided to apply eculizumab in our
young child. The outcome was favourable, with stable, normal
renal function and a significant decrease in proteinuria
11 months after eculizumab treatment was started.
In a patient undergoing RTPL twice, C3NeF and sC5b-9 were
analysed after PEX treatment with FFP had been started, so
detection of both C3NeF and sC5b-9 might have been missed
[58]. This patient experienced aABMR with recurrence of DDD 3
years after the first RTPL and was therefore treated with PEX.
However, he reached ESRD after the first RTPL, with recurrence
of the disease in the second renal graft. Treatment with PEX
was started at weekly intervals but led to only a moderate
decrease in proteinuria with persistently impaired graft func-
tion. The insurance refused to pay for treatment with
Table 3. Patients with RAAS blockers only: values at last follow-up
Characteristic Patient 1 Patient 2 Patient 3
Maintained renal function Native kidney Native kidney Native kidney
Treatment Enalapril Enalapril Enalapril
Losartan Losartan
Duration of observation (years) 9.7 2.2 4.8
eGFR 143 97 180
C3 (g/L) (reference 0.7–1.76) 0.6 <0.06 0.13
UPCR (g/mol) (reference < 20) 41 41 <20
sC3d (mU/L) (reference < 40) 50 103 35
sC5b-9 (ng/mL) (reference < 320) 239 2538 164
eGFR rate according to Schwartz formula in mL/min/1.73 m2.
Table 4. Patients with eculizumab: values before eculizumab and at
last follow-up
Characteristic (original disease)
Patient 4
(MPGN I)
Patient 5
(C3GN)
Maintained renal function Native kidney Native kidney
Additional treatments to
RAAS blockers
PDN
MMF
Before eculizumab
Duration of observation (years) 6.9 9.5
eGFR (mL/min/1.73 m2) 40 100
C3 (g/L) (reference 0.7–1.76) 0.09 0.06
UPCR (g/mol) (reference <20) 510 750
sC3d (mU/L) (reference <40) 63 95
sC5b-9 (ng/mL)
(reference >320)
4100 6500
Observation on eculizumab
Duration of therapy (months) 6 11
eGFR 45 90
UPCR (g/mol) 270 227
sC5b-9 (ng/mL) 282 639
C3 (g/L) 0.12 0.14
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eculizumab. As complement-mediated dysregulation is
involved in the pathophysiology of aABMR [60], it is conceivable
that DDD recurrence may have triggered aABMR by inducing
complement activation. In a recent study, MPGN recurrence
after RTPL was detected in 18 of 40 transplants and in 3 cases
disease recurrence preceded aABMR and led to graft loss [4].
Registries have also reported recurrence rates on renal graft for
DDD and C3G of 50% and 43–67%, respectively [22].
There are some limitations to our study: (i) its retrospective
character; (ii) the individual treatment approach based on the
clinical course; (iii) due to the different time period at disease
manifestation of each patient, no uniformity of treatment was
possible and (iv) measurement of activity of the alternative
pathway (i.e. C3d, sC5b-9) and C3NeF was not available at dis-
ease onset.
Our results reveal that early examination of the alternative
complement pathway may aid to define a more individually
tailored treatment. However, we observed heterogeneity of clin-
ical and biological features in MPGN and C3G and therefore the
difficulty of interpretation of both genetic abnormalities and
biochemical analysis. Long-term observation is necessary in
order to draw conclusions about the results of treatments and
renal function at follow-up.
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